Computer Models More Accurate than Animal Trials
News May 21, 2013
In drug discovery today new drugs are tested on animals, such as rats, dogs and monkeys, to determine whether they are effective and possess sufficient oral bioavailability in these animals.
Up to now, it has been unclear whether animal studies are transferable to humans.
A detailed analysis of the bioavailability knowledge base PACT-F (Preclinical And Clinical Trials Knowledge Base on Bioavailability) from PharmaInformatic, Germany was conducted in order to compare experimental results from animal studies and from human clinical trials. The evaluation was based on more than a hundred approved and marketed drugs.
The research, carried out by PharmaInformatic, has shown that oral bioavailability in animals is inconsistent with the values reported for humans. For many drugs large differences in oral bioavailability were found between humans and animals.
Based on PACT-F, computational models were developed to predict oral bioavailability. The final expert system, called IMPACT-F, calculates human oral bioavailability much more precisely compared to animal trials.
The expert system is a highly reliable way of forecasting oral bioavailability of new drugs. Bioavailability predictions of IMPACT-F were as accurate as the common deviation between individual humans taking part in the same clinical trial.
'It has taken years to develop reliable models, since an excessive amount of clinical data had to be integrated and compared.' says Dr Wolfgang Boomgaarden, founder and CEO of PharmaInformatic. 'Now we have proof that they are significantly more efficient and reliable than animal trials and we hope they will replace useless animal trials soon.'
Every year, millions of animal experiments are carried out. Alternative methods are needed to reduce animal testing. Computational models such as IMPACT-F can replace animal trials. They require no experimental effort, are less expensive and results are almost immediately available. Since they are significantly more reliable than animal models, they will increase the prospects of successful clinical trials in humans.
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE
New Automated Screening Method for Identifying Drug CandidatesNews
Scientists at DESY have developed a new method that enables automated and fast screening of promising drug candidates.READ MORE
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE